In parallel with the prelim clinical data from the three trials in different indications, there will be the pre-clinical data from CDH17 expressing solid tumours via both Autologous Car-T and Allogeniec Car-NK. All eyes in the industry will be on CHM and hence why (perhaps) the timing and preemptive CR plan.
- Forums
- ASX - By Stock
- Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
In parallel with the prelim clinical data from the three trials...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.6¢ |
Change
-0.001(3.03%) |
Mkt cap ! $14.18M |
Open | High | Low | Value | Volume |
1.6¢ | 1.7¢ | 1.6¢ | $10.84K | 677.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 1997996 | 1.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.7¢ | 245189 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1997996 | 0.016 |
10 | 1806477 | 0.015 |
4 | 728475 | 0.014 |
3 | 242223 | 0.013 |
2 | 83412 | 0.012 |
Price($) | Vol. | No. |
---|---|---|
0.017 | 87500 | 1 |
0.018 | 508453 | 2 |
0.019 | 807601 | 5 |
0.020 | 1523093 | 7 |
0.021 | 412857 | 3 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
CHM (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online